-
Information concerning impact of non-diluting incentive program on Company’s financial statements
Read More
May 13, 2021 -
New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Congress 2021
Read More
May 12, 2021 -
Declaration of establishing a non-diluting incentive program in the Company for the years 2021-2024
Read More
April 20, 2021 -
Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) by the FDA in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read More
April 8, 2021 -
Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
April 8, 2021 -
Conclusion of the grant agreement with the National Center for Research and Development
Read More
March 18, 2021 -
Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting
Read More
March 11, 2021 -
Conclusion of an agreement concerning operational execution of Phase I clinical trial of RVU120 (SEL120) in solid tumors
Read More
March 8, 2021 -
Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
Read More
January 18, 2021 -
Publication dates for periodic reports in 2021
Read More
January 13, 2021 -
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Read More
January 7, 2021 -
The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
Read More
January 4, 2021 -
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Read More
December 1, 2020 -
Appointment of the new Management Board Member of Ryvu Therapeutics S.A.
Read More
November 23, 2020 -
Revision of the Company’s research project pipeline
Read More
October 21, 2020 -
Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020
Read More
October 14, 2020 -
Change of the registered office address of Ryvu Therapeutics S.A.
Read More
October 12, 2020 -
First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703
Read More
September 16, 2020 -
Appointment of Members of the Company’s Management and Supervisory Boards for a new term of office
Read More
September 1, 2020 -
Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. held on August 31, 2020
Read More
August 31, 2020
Report: Current Stock Reports
Title